FTI Consulting handles Abcam as the British biotechnology company agrees to a $5.7B takeover from DC-based Danaher Corp., which chalked up $31.5B in fiscal 2022 revenues.

Abcam will operate as a standalone company in Danaher’s life sciences division to bolster its strategy “to help map complex diseases and accelerate the drug discovery process."

Founded in Cambridge in 1998, Abcam’s validated antibodies, reagents, biomarkers and assays are used by an estimated 750K researchers.

Danaher CEO Rainer Blair said Abcam’s long track record of innovation and breadth of antibody portfolio positions makes it a key partner for the scientific community.

The transaction is expected to close mid-2024.